Results 171 to 180 of about 66,181 (261)
Aberrant intra-epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103-β7-receptor-mediated granzyme-B degranulation which can be restored by etrolizumab. [PDF]
Castelijn DAR +18 more
europepmc +1 more source
Natural Killer (NK) cells are potent effectors against virus‐infected and tumour cells. During Friend Virus (FV) infection, fatty acid metabolism supports NK‐cell effector functions. Here, we found that NK cells from FV‐infected mice preferentially take up linoleic acid (LA), which reduced proliferation, mitochondrial function, and increased reactive ...
Vaasudevan Sridhar +8 more
wiley +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Anna Sophia Flechtenmacher +2 more
wiley +1 more source
Unlike generalized mTOR inhibitors, Torin‐1 uniquely drives compensatory upregulation of TIM‐3 on human NK cells, shielding them from immunosuppression while concurrently inhibiting glioblastoma (GBM) growth. Selecting or preconditioning ex vivo NK cell products for high TIM‐3 expression can offer a combination strategy for adoptive cell therapy in GBM.
Yuning Liu +11 more
wiley +1 more source
LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma. [PDF]
Hou X +15 more
europepmc +1 more source
Determinants of T Cell Exhaustion: How Far Back Can We Go?
Classical versus Emerging models of CD8+ T Cell Exhaustion. Comparison of the classical ‘Endpoint Model’ (Left), where exhaustion is viewed as a terminal state requiring reversal, versus the emerging ‘Trajectory Model’ (Right). Recent studies suggest exhaustion is a continuous developmental path initiated early in infection or tumuorigenesis ...
Testimony Olumade +2 more
wiley +1 more source
Distinct cellular dynamics following CD19 and CD7 CAR-T therapies revealed by high-dimensional CyTOF analysis and impact on clinical outcomes. [PDF]
Zhou Z +9 more
europepmc +1 more source
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley +1 more source

